MitoSense, a biotechnology company focused on neurodegenerative disease treatments, announced a $3.5 million seed round led by Caydan Capital Partners. The company aims to replenish damaged mitochondria in patients with degenerative conditions, and it is starting with treating amyotrophic lateral sclerosis.
The company collaborates with organizations such as the Elliott Mitochondrial Research Center to enhance its mitochondrial research capabilities, the James A. Haley Veterans’ Hospital to develop therapies for neurodegenerative dysfunctions in veterans and the Greenwood Genetic Center to research Alzheimer’s and genetic aspects of mitochondrial diseases.
With its latest round of funding MitoSense will advance its work in mitochondria organelle transplantation as it strives to transform the landscape of neurodegenerative disease treatment.
